CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, announced today new data and product enhancements to be presented at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California, from October 21-25, 2024. CareDx focuses on precision medicine, aiming to discover, develop, and commercialize high-value healthcare solutions for transplant patients and their caregivers.
CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, is showcasing its latest advancements in AlloSeq™ NGS-based HLA typing solutions at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California, from October 21-25, 2024. These innovations highlight the clinical utility of HLA typing in living organ donation and bone marrow transplantation. CareDx is also launching an enhanced QTYPE® solution that features single bead antigen resolution for quicker virtual crossmatching in deceased donor typing.
“We are dedicated to providing the most advanced HLA typing solutions to support optimal donor-recipient matching in solid organ and stem cell transplants,” said John W. Hanna, CareDx President and CEO. “We’re excited to present our latest product innovations and supporting data at this year’s ASHI meeting.”
CareDx will host a symposium featuring Annette M. Jackson, PhD, F(ACHI), from Duke University, who will discuss her lab’s findings on risk haplotypes in pediatric nephrotic syndrome. CareDx speakers Curt Lind, PhD, and Beata Kmiec, PhD, will present innovations including a novel approach to HLA haplotyping and advancements to the QTYPE real-time PCR solution, which now offers high coverage redundancy and single antigen resolution in a single run.
Key data to be presented at ASHI 2024 include:
- Validation of AlloSeq Tx 11: This study demonstrates that new probes in AlloSeq Tx 11 enhance sequencing coverage of Class II loci, achieving 99.9% concordance and reducing typing ambiguities.
- Buccal Swab Performance: The AlloSeq Tx 17 hybrid capture method achieved a 100% success rate with fragmented buccal DNA, compared to 43% success with alternative long-range PCR methods.
- 3-D Haplotyping: This innovative approach using LinkPrep™ reagents paired with AlloSeq Tx technology allows for high-resolution genotyping and haplotyping without requiring family studies.
About CareDx – The Transplant Company
CareDx, headquartered in Brisbane, California, is a leader in precision medicine solutions focused on developing clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions throughout the pre- and post-transplant journey and is a top provider of genomics-based information for transplant patients.
